Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
P 1 (3)
P 2 (2)

Trial Status

Recruiting3
Active Not Recruiting1
Withdrawn1
Suspended1

Clinical Trials (6)

Showing 6 of 6 trials
NCT04803201Phase 2Suspended

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

NCT05377827Phase 1Active Not Recruiting

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

NCT05475925Phase 1Recruiting

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

NCT06692452Phase 2Withdrawn

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

NCT07388563Phase 1Recruiting

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT05978141Recruiting

A Registry for People With T-cell Lymphoma

Showing all 6 trials

Research Network

Activity Timeline